{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Tavera RJ"],"funding":["NCI NIH HHS"],"pagination":["399-405"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6177302"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["41(9)"],"pubmed_abstract":["In this study, we address one of the major critiques for tumor-infiltrating lymphocyte (TIL) therapy-the time needed for proper expansion of a suitable product. We postulated that T-cell receptor activation in the first phase of expansion combined with an agonistic stimulation of CD137/4-1BB and interleukin-2 would favor preferential expansion of CD8 TIL. Indeed, this novel 3-signal approach for optimal T-cell activation resulted in faster and more consistent expansion of CD8CD3 TIL. This new method allowed for successful expansion of TIL from cutaneous and uveal melanoma tumors in 100% of the cultures in <3 weeks. Finally, providing the 3 signals attributed to optimal T-cell activation led to expansion of TIL capable of recognizing their tumor counterpart in cutaneous and uveal melanoma. "],"journal":["Journal of immunotherapy (Hagerstown, Md. : 1997)"],"pubmed_title":["Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma."],"pmcid":["PMC6177302"],"funding_grant_id":["P30 CA016672"],"pubmed_authors":["Forget MA","Haymaker C","Ramachandran R","Fulbright OJ","Bernatchez C","Flores E","Sakellariou-Thompson D","Thorsen ST","Wahl A","Bhatta A","Gonzalez AM","Kim YU","Hwu P","Mansaray R","Creasy CA","Toth C","Radvanyi LG","Wardell S","Gombos DS","Patel SP","Amaria RN","Tavera RJ"],"additional_accession":[]},"is_claimable":false,"name":"Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma.","description":"In this study, we address one of the major critiques for tumor-infiltrating lymphocyte (TIL) therapy-the time needed for proper expansion of a suitable product. We postulated that T-cell receptor activation in the first phase of expansion combined with an agonistic stimulation of CD137/4-1BB and interleukin-2 would favor preferential expansion of CD8 TIL. Indeed, this novel 3-signal approach for optimal T-cell activation resulted in faster and more consistent expansion of CD8CD3 TIL. This new method allowed for successful expansion of TIL from cutaneous and uveal melanoma tumors in 100% of the cultures in <3 weeks. Finally, providing the 3 signals attributed to optimal T-cell activation led to expansion of TIL capable of recognizing their tumor counterpart in cutaneous and uveal melanoma. ","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Nov/Dec","modification":"2026-05-03T19:06:41.153Z","creation":"2019-11-07T08:01:04Z"},"accession":"S-EPMC6177302","cross_references":{"pubmed":["29757889"],"doi":["10.1097/cji.0000000000000230","10.1097/CJI.0000000000000230"]}}